Back to Search
Start Over
Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalence.
- Source :
-
The journal of allergy and clinical immunology. Global [J Allergy Clin Immunol Glob] 2023 May; Vol. 2 (2), pp. 100092. - Publication Year :
- 2023
-
Abstract
- Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in young children and is associated with subsequent recurrent wheezing illness and asthma (wheeze/asthma). RSV prevention may therefore reduce wheeze/asthma prevalence.<br />Objectives: We estimated the contribution of RSV LRTI and the impact of RSV prevention on recurrent wheeze/asthma in Mali.<br />Methods: We simulated 12 consecutive monthly birth cohorts in Mali and estimated RSV LRTI cases through 2 years and recurrent wheeze/asthma prevalence at 6 years under different RSV prevention scenarios: status quo, seasonal birth-dose extended half-life mAb, and seasonal birth-dose extended half-life mAb followed by 2 doses of pediatric vaccine (mAb + vaccine). We used World Health Organization (WHO) Preferred Product Characteristics for RSV prevention, demographic and RSV epidemiologic data from Mali, regional recurrent wheeze/asthma prevalence, and relative risk of recurrent wheeze/asthma given early childhood RSV LRTI.<br />Results: Among the simulated cohort of 778,680 live births, 10.0% had RSV LRTI by 2 years and 89.6% survived to 6 years. We estimated that 13.4% of all recurrent wheeze/asthma at 6 years was attributable to RSV LRTI. Recurrent wheeze/asthma prevalence at 6 years was 145.0 per 10,000 persons (RSV LRTI attributable) and 1084.2 per 10,000 persons (total). In mAb and mAb + vaccine scenarios, RSV LRTI cases decreased by 11.8% and 44.4%, respectively, and recurrent wheeze/asthma prevalence decreased by 11.8% and 44.4% (RSV LRTI attributable) and 1.6% and 5.9% (total).<br />Conclusion: In Mali, RSV prevention programs may have a meaningful impact on chronic respiratory disease, strengthening the case for investment in RSV prevention.<br /> (© 2023 The Authors.)
Details
- Language :
- English
- ISSN :
- 2772-8293
- Volume :
- 2
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- The journal of allergy and clinical immunology. Global
- Publication Type :
- Academic Journal
- Accession number :
- 37215432
- Full Text :
- https://doi.org/10.1016/j.jacig.2023.100092